26
Jan
2012
SARcode, Inc.: Series B $44M
Posted in I - Series B, Q - 3Q11, R - WEST, X - Dermatology, X - Inflammation, X - Opthalmology, XX - CA
SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners. Thanx for your patience as we catch-up.
16
May
2011
07
Mar
2011
21
Feb
2011
Chimerix, Inc.: Series F $45M
Posted in I - Series F, Q - 1Q11, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC
Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.
16
Feb
2011
PneumRx, Inc.: Series C $33M
Posted in I - Series C, Q - 1Q11, R - WEST, X - Device (Emphysema), XX - CA
PneumRx (Mountain View, CA) a development-stage medical device company focused on improve lung function associated with emphysema, closed a $33M Series C financing. Participants include Forbion Capital Partners, Endeavour Vision, Adams Street Partners, Telegraph Hill Partners, Alta Partners, Spray Venture Partners and Leader Ventures.
08
Dec
2010
Ceregene, Inc.: Series D $11.5M
Posted in I - Series D, Q - 4Q10, R - WEST, X - Alzheimer's, X - Gene Therapy, X - Parkinson's, XX - CA
Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.
30
Nov
2010
Sutro Biopharma, Inc.: Series C $36.5M
Posted in I - Series C, Q - 4Q10, R - WEST, X - Therapeutic Platform, XX - CA
Sutro Biopharma (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, closed a $36.5M Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.
19
Nov
2010
09
Nov
2010
Pathwork Diagnostics, Inc.: Series C $30M
Posted in I - Series C, Q - 4Q10, R - WEST, X - Device (Diagnostic), X - Oncology, XX - CA
Pathwork Diagnostics (Redwood City, CA) a commercial-stage molecular diagnostics company focused on tumor RNA expression patterns, closed a $30M Series C financing, it announced. Participants include Alta Partners, Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners and Venrock.
25
Oct
2010
Cara Therapeutics, Inc.: Series D $15M
Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Inflammation, X - Pain, XX - CT
Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.
25
Oct
2010
18
Oct
2010
Cerenis Therapeutics, SA: Series C $40M
Posted in I - Series C, Q - 3Q10, R - INTERNATIONAL, X - Atherosclerosis, X - Cardiology, X - HDL
Cerenis Therapeutics (France), a clinical-stage biopharmaceutical company focused on the regression of atherosclerotic plaque and the enhancement of HDL function, closed a $40M Series C financing. Participants include Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
16
Aug
2010
Calistoga Pharmaceuticals, Inc.: Series C $40M
Posted in I - Series C, Q - 3Q10, R - NORTH WEST, X - Inflammation, X - Oncology, X - PI3K, XX - WA
Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.
OnBioVC PARTNERS
-
